KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) EBT Margin (2016 - 2025)

Historic EBT Margin for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to 14.05%.

  • Neogenomics' EBT Margin fell 34200.0% to 14.05% in Q3 2025 from the same period last year, while for Sep 2025 it was 16.07%, marking a year-over-year decrease of 36800.0%. This contributed to the annual value of 12.21% for FY2024, which is 42000.0% up from last year.
  • Latest data reveals that Neogenomics reported EBT Margin of 14.05% as of Q3 2025, which was down 34200.0% from 25.27% recorded in Q2 2025.
  • In the past 5 years, Neogenomics' EBT Margin ranged from a high of 60.33% in Q2 2021 and a low of 45.37% during Q1 2022
  • Moreover, its 5-year median value for EBT Margin was 18.13% (2023), whereas its average is 16.32%.
  • Its EBT Margin has fluctuated over the past 5 years, first soared by 809700bps in 2021, then crashed by -931400bps in 2022.
  • Neogenomics' EBT Margin (Quarter) stood at 35.16% in 2021, then skyrocketed by 48bps to 18.4% in 2022, then surged by 47bps to 9.83% in 2023, then grew by 5bps to 9.38% in 2024, then tumbled by -50bps to 14.05% in 2025.
  • Its last three reported values are 14.05% in Q3 2025, 25.27% for Q2 2025, and 15.27% during Q1 2025.